Future Horizons: Innovations in Drug Formulation and Delivery for Sunitinib Malate
The global Sunitinib Malate Market is an integral segment of the broader oncology therapeutics landscape, driven by the rising prevalence of cancer and the increasing adoption of targeted therapies. According to the Polaris Market Research report, the market was valued at USD 105.22 million in 2022 and is projected to reach USD 278.54 million by 2032 , growing at a CAGR of 10.60% during the forecast period. This growth reflects expanding clinical applications, regulatory approvals, and advancements in precision oncology. Oncology Drug Market Report and Sunitinib Research Insights A comprehensive oncology drug market report highlights the growing importance of targeted therapies like sunitinib malate in cancer treatment. Sunitinib malate is a multi-targeted tyrosine kinase inhibitor that works by blocking proteins responsible for tumor growth and angiogenesis. The increasing global cancer burden is a primary growth driver. According to available data, cancer accounted for...